Trial · NCT02192541
Results by group42
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 42
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | Grade 3 Abdominal Pain | 1 | Participants | |
| Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | Grade 3 Abdominal Pain | 0 | Participants | |
| Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | Grade 3 Alkaline Phosphtase Increased | 0 | Participants | |
| Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | Grade 3 Alkaline Phosphtase Increased | 1 | Participants | |
| Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | Grade 3 Gastritis* | 1 | Participants | |
| Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | Grade 3 Gastritis* | 0 | Participants | |
| Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | Grade 5 Small Intestinal Perforation* | 1 | Participants | |
| Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | Grade 5 Small Intestinal Perforation* | 0 | Participants | |
| Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | Grade 5 Sudden Death Not Otherwise Specified* | 0 | Participants | |
| Number of Participants With Grade 2 or Greater Adverse Events Possibly, Probably, or Definitely Related to Administration of the Study Drugs | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | Grade 5 Sudden Death Not Otherwise Specified* | 1 | Participants | |
| Number of Participants According to Best Response Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | Complete Response | 0 | Participants | |
| Number of Participants According to Best Response Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | Complete Response | 0 | Participants | |
| Number of Participants According to Best Response Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | Partial Response | 0 | Participants | |
| Number of Participants According to Best Response Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | Partial Response | 0 | Participants | |
| Number of Participants According to Best Response Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | Stable Disease | 0 | Participants | |
| Number of Participants According to Best Response Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | Stable Disease | 3 | Participants | |
| Number of Participants According to Best Response Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | Progressive Disease | 1 | Participants | |
| Number of Participants According to Best Response Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | Progressive Disease | 0 | Participants | |
| Number of Cycles on Treatment | Dose Level 1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 4 mg/kg | 1 | Full Range 1 to 1 | cycles | |
| Number of Cycles on Treatment | Dose Level -1: Ganetespib 100 mg/m^2 + Ziv-Aflibercept 3 mg/kg | 4 | Full Range 4 to 5 | cycles |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02192541/results?page=2